Dai Maruyama, Erica J. Gomez, Muhammad Jalaluddin, Kamel Izeradjene, Edward Greenberg, Cyril Ramathal, Matthew Ku. "A phase 1 first-in-human study evaluating safety, pharmacokinetics, and efficacy of ABBV-291, a CD79b-targeting antibody-drug conjugate, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.tps7093